Cannabigerol - 20 mg/ml solution in methanol

CAS : 25654-31-3

Ref. 3D-FC42726

Informations sur le produit

• Nom: Cannabigerol - 20 mg/ml solution in methanol
• Synonymes: CBG, (E)-2-(3,7-Dimethylocta-2,6-dien-1-yl)-5-pentylbenzene-1,3-diol, 1,3-Benzenediol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-, 1,3-Benzenediol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-, (E)-, 1,3-Benzenediol, 2-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]-5-pentyl-, 1,3-Benzenediol, 2-[(2E)-3,7-dimethyl-2,6-octadienyl]-5-pentyl-, 2-((2E)-3,7-Dimethylocta-2,6-dienyl)-5-pentylbenzene-1,3-diol, 2-[(2E)-3,7-Dimethyl-2,6-octadien-1-yl]-5-pentyl-1,3-benzenediol, Cannabigerol, Resorcinol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-, Resorcinol, 2-(3,7-dimethyl-2,6-octadienyl)-5-pentyl-, (E)-

Description

Cannabigerol is a non-psychotropic phytocannabinoid which has a low affinity for the CB1 and CB2 receptors but affects the endocannabinoid system by inhibiting anandamide uptake (Morales, 2017). It also acts as a potent alpha2+adrenoceptor agonist (EC50= 0.2 nM) (Cascio, 2010). In vitro, cannabigerol was shown to reduce cell loss viability and inhibit apoptosis in motor neurons as well as reducing inflammatory cytokine levels in neural cultures. In in vivo experimental animal models it was shown to antagonize the 5-HT1A receptor (Kb= 51.9 nM) (Cascio, 2010), inhibit vas deferens contractions via a2 adrenoceptor mediation as well as improve motor deficits and prevent neurotoxicity and the upregulation of proinflammatory markers on striatal neurons in mice models (Valdeolivas, 2015).

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 316.48 g/mol
• Formule: C₂₁H₃₂O₂
• Degré de pureté: Min. 95%
• Couleur/Forme: Clear Liquid